

Please [join us](#)

## IASLC 2022 World Conference on Lung Cancer Industry Sponsored Symposium

**SATURDAY, AUGUST 6<sup>TH</sup>, 2022 10:45 – 11:45 CEST**  
Messe Wien Exhibition & Congress Center, Vienna, Austria

# c-Met dysregulation: Targeted agents and their emerging role in advanced NSCLC

## Session Overview

With the evolution of new cancer treatments, novel complex molecules carry the promise to deliver more targeted and more potent activity against c-Met dysregulation. Will these agents live up to the expectation? Under these circumstances, patient selection will be critical.

It is **our pleasure to invite you** to our symposium as we discuss the recent evidence and explore the following questions:



What are the current challenges associated with biomarker testing in NSCLC?



What is the role of c-Met dysregulation in NSCLC?



What is the available data on the use of agents targeting c-Met dysregulation in NSCLC?

## Faculty



### CHAIR

**Jair Bar, M.D., Ph.D.**

Associate Prof. of Oncology,  
School of Medicine, Tel Aviv University,  
Tel Aviv, Israel,  
Deputy Director, Institute of Oncology,  
Sheba Medical Center,  
Ramat Gan, Israel



**Shobhit Baijal, M.D.**

Consultant Medical Oncologist  
University Hospital Birmingham  
NHS Trust,  
Birmingham, UK



**Alona Zer, M.D.**

Head, Department of Medical  
Oncology, Oncology Institute  
Rambam Health Care Campus  
Haifa, Israel

Topic	Speaker
Introduction	Prof. Jair Bar
c-Met testing and challenges associated with biomarker testing in NSCLC	Prof. Jair Bar
Role of c-Met dysregulation in NSCLC	Dr. Shobhit Baijal
Clinical data available on agents targeting c-Met dysregulation in NSCLC	Dr. Alona Zer
Q&A	Panel
Conclusion and Evaluation	Prof. Jair Bar

We look forward to [welcoming you](#) to this symposium

This program was approved by the IASLC 2022 World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 2022 World Conference on Lung Cancer.  
This program is not sponsored or endorsed by IASLC and is not part of the official IASLC accredited program.  
This Industry Sponsored Symposium is organized and sponsored by AbbVie Inc.  
The symposium contains information on uses of investigational compounds that have not been approved, safety and efficacy are not yet established.

abbvie

cMET-AA-00035-E, V1.0  
Approved, June 2022